A Study of GEn-1124 in Subjects with Acute Respiratory Distress Syndrome (ARDS)

Purpose

GEn1E-1124-002 is a two-part Phase 2 study to evaluate the safety and tolerability of GEn-1124 in subjects with ARDS. Treatment with IV infusion dosing as early as possible after ARDS diagnosis. Subjects will be given a second dose approximately 8 hours after the first dose and will continue with twice daily dosing (BID regimen) for 5 days.

Condition

  • Respiratory Distress Syndrome, Acute

Eligibility

Eligible Ages
Between 18 Years and 80 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Male or female subject between the ages of 18 and 80 years old, inclusive. 2. Written informed consent . 3. Dosing as early as possible after first meeting ARDS 2023 Global definition. 4. Acceptable method of birth control.

Exclusion Criteria

  1. Subject, surrogate, or physician not committed, or eligible, to receive full supportive care measures. 2. Pregnant or breastfeeding 3. Currently incarcerated in a correctional institution or involuntarily committed to an inpatient mental health facility. 4. Active malignancy (other than non-melanoma skin cancer) requiring treatment within the last 3 months or within the last 6 months if an anti-B cell antibody was received. 5. Any other irreversible disease or condition for which 6-month mortality is estimated to be >50%. 6. Moderate to severe liver failure. 7. Estimated glomerular filtration rate (eGFR) <10 mL/min/1.73 m2 or requiring dialysis at screening. 8. Acute Left ventricular failure or congestive heart failure, defined as New York Heart Association Class IV. 9. Severe chronic respiratory disease with continuous home oxygen >2 liters per minute (LPM) or >28% (adjusted for altitude); and/or home noninvasive ventilation (except for the treatment of obstructive sleep apnea). 10. Poly-traumatic injury resulting in significant blood loss and/or likely to require major surgery within the study period, or subject condition that would interfere with study procedures. 11. History of any type of solid organ or cellular transplant. 12. Receiving immunosuppressive therapy for solid organ or hematopoietic cancer, transplant anti-rejection medication, and/or other chronic conditions. 13. Moribund subject not expected to survive 24 hours. 14. Do not resuscitate (DNR) status. 15. World Health Organization (WHO) functional class III or IV pulmonary hypertension. 16. Burn victims currently undergoing treatment for >20% total body surface area (TBSA) involvement or for known airway inhalation injury. 17. Neuromuscular disease that could impact ability to wean from mechanical ventilation. 18. History of tuberculosis (TB); undergoing treatment for latent TB infection (LTBI); untreated LTBI (as determined by documented results within 3 months of Screening of a positive TB test). 19. Active Hepatitis B, positive Hepatitis C (and has not completed antiviral treatment), or positive human immunodeficiency (HIV) screen. 20. Use of any investigational drug or device within last 30 days of dosing or 5 half-lives, whichever is longer. 21. Any other medical, psychiatric, or social condition that, in the opinion of the investigator, is likely to unfavorably alter the risk-benefit of subject participation, to interfere with protocol compliance, or to confound safety.

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Sequential Assignment
Intervention Model Description
Part 1 - Randomized, double-blind, dose escalation. Part 2 - Randomized, double-blind, placebo controlled, parallel group.
Primary Purpose
Treatment
Masking
Triple (Participant, Care Provider, Investigator)
Masking Description
All subjects, investigators, and study personnel involved in the conduct of the study, including data management, will be blinded to treatment assignment with the exception of some designated personnel. The unblinded study personnel will not participate in study procedures or data analysis prior to unblinding of the study data to all study-related personnel.

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Part 1 Cohort 1: GEn-1124 		Subjects in cohort 1 will receive low dose GEn-1124 BID intravenous 5 days.
  • Drug: GEn-1124
    Intravenous infusion
Experimental
Part 1 Cohort 2: GEn-1124 		Subjects in cohort 2 will receive high dose GEn-1124 BID intravenous for 5 days.
  • Drug: GEn-1124
    Intravenous infusion
Placebo Comparator
Placebo 		Subjects randomized to placebo will receive a placebo in a matching dosing regimen (Placebo BID intravenous for 5 days).
  • Drug: Placebo
    Intravenous infusion
Experimental
Part 2: GEn-1124 		Depending on the analysis of part 1, subjects in part 2 will receive GEn-1124 BID intravenous for 5 days.
  • Drug: GEn-1124
    Intravenous infusion

Recruiting Locations

University of Kansas Medical Center
Kansas City, Kansas 66160

More Details

Status
Recruiting
Sponsor
GEn1E Lifesciences

Study Contact

Ritu Lal, PhD, MS
(650) 248-2429
clinical@gen1elifesci.com

Detailed Description

Randomized , double-blind, placebo controlled, dose escalation study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of GEn1124. GEn-1124 or placebo will be administered as a 2-hour IV infusion as early as possible after ARDS diagnosis. Participants will receive a second dose approximately 8 hours after the first and will continue BID for the remaining schedule (Days 2-5). Follow-up will be for a total of 60 days after the first dose or death (whichever comes first). An independent Safety Review Committee (SRC) will be responsible for reviewing data throughout the study.